Clinical Trial Update: Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506) [Phase 2]

View source ↗

Summary

Phase 2 study assessing the safety and tolerability of once-daily inhaled ciclesonide and formoterol fumarate in adults with asthma; the trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Ciclesonide and Formoterol Fumarate Inhalation (once daily) (ciclesonide and formoterol fumarate)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 2 | Status: COMPLETED